Jefferies analyst Akash Tewari upgraded Regeneron Pharmaceuticals to Buy from Hold with a price target of $925, up from $675. Dupixent "well exceeded" the buy-side bar, showing a 30% reduction over placebo in patients with uncontrolled chronic obstructive pulmonary disease, the analyst tells investors in a research note. The firm thinks COPD could be a $4B opportunity for Dupixent and also increased Regeneron’s IL-33 sales potential to $2Bn given the signal in non-smokers. Despite the macro environment, Regeneron "hit two home runs within a short period of time" with Eylea data and Dupixent in COPD, contends Jefferies.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron May Win Big with New Drug
- Raymond James ups Regeneron to Market Perform as few downside catalysts remain
- Regeneron upgraded to Market Perform from Underperform at Raymond James
- Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints
- Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial